Delving into the Latest Updates on Thrasos Therapeutics, Inc. with Synapse

概览

关联

4

项与 Thrasos Therapeutics, Inc. 相关的药物

THR-8590

靶点

UMOD

作用机制

UMOD调节剂

在研机构-

原研机构

Thrasos Therapeutics, Inc.

在研适应症-

非在研适应症

急性肾损伤

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

AA-123

靶点

BMPR1A

作用机制

BMPR1A刺激剂

在研机构-

原研机构

Thrasos Therapeutics, Inc.

在研适应症-

非在研适应症

前列腺癌

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

AA 166

靶点

BMPR1A

作用机制

BMPR1A刺激剂

在研机构-

原研机构

Thrasos Therapeutics, Inc.

在研适应症-

非在研适应症

乳腺癌 [+4]

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

1

项与 Thrasos Therapeutics, Inc. 相关的临床试验

NCT01830920 / Completed临床2期

A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)

The purpose of this study is to determine whether THR-184 when administered around the time of cardiac surgery that requires cardiopulmonary bypass can prevent or ameliorate the development of acute kidney injury.

开始日期2013-05-01

申办/合作机构

Thrasos Therapeutics, Inc.

100 项与 Thrasos Therapeutics, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Thrasos Therapeutics, Inc. 相关的专利（医药）

登录后查看更多信息

3

项与 Thrasos Therapeutics, Inc. 相关的文献（医药）

2018-02-01·Journal of the American Society of Nephrology1区 · 医学

Perioperative THR-184 and AKI after Cardiac Surgery

1区 · 医学

Article

作者: Dagenais, François ; Shaw, Andrew D ; Rossert, Jerome ; Mesana, Thierry ; Cortville, David ; Brown, Craig ; de Varennes, Benoit ; Tardif, Jean-Claude ; Chertow, Glenn M ; Fontes, Manuel ; Himmelfarb, Jonathan ; Sundt, Thoralf M ; McCullough, Peter A

AKI after cardiac surgery is associated with mortality, prolonged hospital length of stay, use of dialysis, and subsequent CKD. We evaluated the effects of THR-184, a bone morphogenetic protein-7 agonist, in patients at high risk for AKI after cardiac surgery. We conducted a randomized, double-blind, placebo-controlled, multidose comparison of the safety and efficacy of perioperative THR-184 using a two-stage seamless adaptive design in 452 patients between 18 and 85 years of age who were scheduled for nonemergent cardiac surgery requiring cardiopulmonary bypass and had recognized risk factors for AKI. The primary efficacy end point was the proportion of patients who developed AKI according to Kidney Disease Improving Global Outcomes (KDIGO) criteria. The proportion of patients who developed AKI within 7 days of surgery was similar in THR-184 treatment groups and placebo groups (range, 74%-79%; P=0.43). Prespecified secondary end point analysis did not show significant differences in the severity of AKI stage (P=0.53) or the total duration of AKI (P=0.44). A composite of death, dialysis, or sustained impaired renal function by day 30 after surgery did not differ between groups (range, 11%-20%; P=0.46). Safety-related outcomes were similar across all treatment groups. In conclusion, compared with placebo, administration of perioperative THR-184 through a range of dose exposures failed to reduce the incidence, severity, or duration of AKI after cardiac surgery in high-risk patients.

2017-10-01·Kidney International Supplements1区 · 医学

Genetic and environmental risk factors for chronic kidney disease

1区 · 医学

Review

作者: Langham, Robyn G ; Pecoits-Filho, Roberto ; Fox, Caroline S ; Rossert, Jerome ; Stenvinkel, Peter ; Nangaku, Masaomi ; Obrador, Gregorio T ; Correa-Rotter, Ricardo ; Schultheiss, Ulla T ; Kretzler, Matthias ; Pollock, Carol ; Köttgen, Anna ; Walker, Robert ; Yang, Chih-Wei

In order to change the current state of chronic kidney disease knowledge and therapeutics, a fundamental improvement in the understanding of genetic and environmental causes of chronic kidney disease is essential. This article first provides an overview of the existing knowledge gaps in our understanding of the genetic and environmental causes of chronic kidney disease, as well as their interactions. The second part of the article formulates goals that should be achieved in order to close these gaps, along with suggested timelines and stakeholders that are to be involved. A better understanding of genetic and environmental factors and their interactions that influence kidney function in healthy and diseased conditions can provide novel insights into renal physiology and pathophysiology and result in the identification of novel therapeutic or preventive targets to tackle the global public health care problem of chronic kidney disease.

2017-10-01·Kidney International Supplements1区 · 医学

The establishment and validation of novel therapeutic targets to retard progression of chronic kidney disease

1区 · 医学

Review

作者: Yang, Chih-Wei ; Remuzzi, Giuseppe ; Pollock, Carol ; Pecoits-Filho, Roberto ; Langham, Robyn G ; Zuk, Anna ; Bonventre, Joseph V ; Kasiske, Bertram ; Anders, Hans-Joachim ; Suzuki, Yusuke ; Johnson, David W ; Tanaka, Tetsuhiro ; Rossert, Jerome ; Ganji, Mohammad Reza ; Walker, Robert

The focus of this article is to define goals and resulting action plans that can be collectively embraced by interested stakeholders to facilitate new therapeutic approaches to mitigate chronic kidney disease progression. The specific goals include identifying druggable targets, increasing the capacity for preclinical and early clinical development, broadening the availability of new therapeutic approaches, and increasing investment in the development of new therapies to limit chronic kidney disease. Key deliverables include the establishment of new regional, national, and global consortia; development of clinical trial networks; and creation of programs to support the temporary mutual movement of scientists between academia and the biotechnology and pharmaceutical sector. Other deliverables include cataloging and maintaining up-to-date records to collate progress in renal research and development, inventorying the capacity of research and clinical networks, and describing methods to ensure novel drug development.

100 项与 Thrasos Therapeutics, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Thrasos Therapeutics, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年12月23日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

其他

4

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

THR-8590 ( UMOD )	急性肾损伤更多	终止
THR-184 ( BMPR1A )	科凯恩氏综合症更多	无进展
AA-123 ( BMPR1A )	前列腺癌更多	无进展
AA 166 ( BMPR1A )	肥胖更多	无进展